Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone)
| العنوان: | Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone) |
|---|---|
| المؤلفون: | Nienke J de Boer-Veger, Vera H.M. Deneer, Ron H.N. van Schaik, Gerard A. Rongen, Jan van der Weide, Henk-Jan Guchelaar, Bob Wilffert, Bianca Soree, Marga Nijenhuis, Hans Mulder, Elisa J. F. Houwink, Maja Matic, Jesse J. Swen, Anne-Marie Buunk |
| المساهمون: | Clinical Chemistry, Reproductive Origins of Adult Health and Disease (ROAHD) |
| المصدر: | European journal of human genetics : EJHG European Journal of Human Genetics. SPRINGERNATURE European Journal of Human Genetics European Journal of Human Genetics, 30(10). Nature Publishing Group European Journal of Human Genetics, 30, 1105-1113 European Journal of Human Genetics. Nature Publishing Group European Journal of Human Genetics, 30, 10, pp. 1105-1113 |
| بيانات النشر: | Nature Publishing Group, 2022. |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | medicine.medical_specialty, PHARMACOKINETICS, IMPACT, Vascular damage Radboud Institute for Health Sciences [Radboudumc 16], Analgesic, PUPILLOMETRY, digestive system, TOXICITY, MORPHINE, IMPLEMENTATION CONSORTIUM, RESPIRATORY DEPRESSION, Internal medicine, Genetics, medicine, Genetics (clinical), business.industry, Codeine, PAIN, Guideline, Drug interaction, GENOTYPE, Morphine, Tramadol, business, Oxycodone, Pharmacogenetics, POOR METABOLIZERS, medicine.drug |
| الوصف: | Contains fulltext : 286843.pdf (Publisher’s version ) (Closed access) The current Dutch Pharmacogenetics Working Group (DPWG) guideline, describes the gene-drug interaction between CYP2D6 and the opioids codeine, tramadol and oxycodone. CYP2D6 genotype is translated into normal metaboliser (NM), intermediate metaboliser (IM), poor metaboliser (PM) or ultra-rapid metaboliser (UM). Codeine is contraindicated in UM adults if doses >20 mg every 6 h (q6h), in children ≥12 years if doses >10 mg q6h, or with additional risk factors. In PMs, an alternative analgesic should be given which is not or to a lesser extent metabolised by CYP2D6 (not tramadol). In IMs with insufficient analgesia, a higher dose or alternative analgesic should be given. For tramadol, the recommendations for IMs and PMs are the same as the recommendation for codeine and IMs. UMs should receive an alternative drug not or to a lesser extent metabolised by CYP2D6 or the dose should be decreased to 40% of the commonly prescribed dose. Due to the absence of effect on clinical outcomes of oxycodone in PMs, IMs and UMs no action is required. DPWG classifies CYP2D6 genotyping for codeine "beneficial" and recommends testing prior to, or shortly after initiation of treatment in case of higher doses or additional risk factors. CYP2D6 genotyping is classified as "potentially beneficial" for tramadol and can be considered on an individual patient basis. |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 1476-5438 1018-4813 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a70ed9f97daf574c262af2f4b66fef2e https://pure.eur.nl/en/publications/08d928d6-5a3d-46af-b172-b5bb4ae4354d |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....a70ed9f97daf574c262af2f4b66fef2e |
| قاعدة البيانات: | OpenAIRE |
Find this article in full text from Springer Verlag. | تدمد: | 14765438 10184813 |
|---|